Previous 10 | Next 10 |
MALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company received alignment from FDA on key aspe...
RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ce...
MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the fir...
MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the fir...
2023-11-09 11:45:16 ET Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q3 2023 Earnings Call Nov 09, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen (OCGN) Q3 2023 Earnings Call Transcript
2023-11-09 09:45:24 ET Ocugen, Inc. (OCGN) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Tiffany Hamilton - Head of Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer and Co-Founder Michael Breininger...
2023-11-09 06:32:09 ET More on Ocugen Ocugen (OCGN) Q2 2023 Earnings Call Transcript Ocugen Q3 2023 Earnings Preview Ocugen mucosal vaccine selected for U.S. COVID vaccine initiative Seeking Alpha’s Quant Rating on Ocugen Historical earnings da...
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed dosing of three LCA patients including a pediatric patient OCU400 Phase 1...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Ocugen, Inc. (OCGN) is expected to report $-0.08 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...